Ian Gourley
Director Técnico/Científico/I+D en IMMUNOVANT, INC. .
Perfil
Ian Gourley currently works at The Royal College of Physicians, as Member and Immunovant, Inc., as Vice President-Clinical Development.
Dr. Gourley also formerly worked at Eli Lilly & Co., as Head-Clinical Research Pathologist and Janssen Pharmaceuticals, Inc., as Head-Translational Medical Science.
Dr. Gourley received his graduate degree from Queen's University of Belfast.
Cargos activos de Ian Gourley
Empresas | Cargo | Inicio |
---|---|---|
IMMUNOVANT, INC. | Director Técnico/Científico/I+D | - |
The Royal College of Physicians | Corporate Officer/Principal | - |
Antiguos cargos conocidos de Ian Gourley.
Empresas | Cargo | Fin |
---|---|---|
ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
Janssen Pharmaceuticals, Inc.
Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. | Corporate Officer/Principal | - |
Formación de Ian Gourley.
Queen's University of Belfast | Graduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
IMMUNOVANT, INC. | Health Technology |
ELI LILLY AND COMPANY | Health Technology |
Empresas privadas | 1 |
---|---|
Janssen Pharmaceuticals, Inc.
Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. | Health Technology |
- Bolsa de valores
- Insiders
- Ian Gourley